ArticleInternational journal of geriatric psychiatry2022
Potential eligibility for Aducanumab therapy in an Irish specialist cognitive service-Utilising cerebrospinal fluid biomarkers and appropriate use criteria.
Article in International journal of geriatric psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- Eligibility for donanemab trial in a population-based study of cognitive aging.The journal of prevention of Alzheimer's disease · 2025Trial
- Real-World Patient Eligibility for Alzheimer's Disease Anti-Amyloid Therapy in Seven Swedish Memory Clinics.European journal of neurology · 2026Article
- Multimorbidity in dementia: Current perspectives and future challenges.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- BRAIN-Diabetes: a randomised trial to test the feasibility of an adapted FINGER multidomain intervention in adults with type 2 diabetes living in rural border regions of Ireland.European journal of ageing · 2025Article
- Patient eligibility for amyloid-targeting immunotherapies in Alzheimer's disease.The journal of prevention of Alzheimer's disease · 2025Article
- Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer's disease to individuals with mild cognitive impairment or early Alzheimer's disease in the general population.European journal of epidemiology · 2025Article
- Mild cognitive impairment and early Alzheimer's disease eligibility for disease modification therapies in a tertiary centre for cognitive disorders: A simultaneous real-word study on aducanumab and lecanemab.European journal of neurology · 2025Article
- Article
- Eligibility for antiamyloid treatment: preparing for disease-modifying therapies for Alzheimer's disease.Journal of neurology, neurosurgery, and psychiatry · 2024Article
- Navigating the future of Alzheimer's care in Ireland - a service model for disease-modifying therapies in small and medium-sized healthcare systems.BMC health services research · 2024Article
- Real-word application of the AT(N) classification and disease-modifying treatment eligibility in a hospital-based cohort.Journal of neurology · 2024Article
- New horizons in the diagnosis and management of Alzheimer's Disease in older adults.Age and ageing · 2024Review
- Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.Neurology · 2023Article
- Potential eligibility for Aducanumab therapy in an Irish specialist cognitive service-Utilising cerebrospinal fluid biomarkers and appropriate use criteria.International journal of geriatric psychiatry · 2022Article
- Lecanemab real-world treatment outcomes from cohort study in early Alzheimer's disease.Journal of Alzheimer's disease reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesAducanumab is a monoclonal antibody which has recently been licenced for use by the food and drug administration for treatment of patients with mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia. Appropriate use criteria (AUC) for Aducanumab in clinical practice are available. We look to review patients in our specialist interdisciplinary cognitive service with positive cerebrospinal fluid (CSF) biomarkers for AD for their hypothetical eligibility for Aducanumab, or a similar anti-amyloid agent.
methodsRetrospective analysis was undertaken of patients with positive AD-biomarker CSF analysis. Data available at time of CSF analysis was reviewed to determine hypothetical eligibility for Aducanumab.
resultsSeventy patients had positive AD-CSF biomarkers. Forty nine of these were seen in the Gerontology-led service, with 21 in the neurology cohort. Average patient age was 70 years old. Forty patients (57%) met eligibility criteria for Aducanumab therapy by AUC guidelines.
conclusionWe highlight the patients within our service who would be appropriate for Aducanumab or similar anti-amyloid agents should licencing be granted in the European Union, and the need to develop the resources and capacity to deliver this or other emerging disease modifying AD therapies. CLINICAL
trial registrationAll patients in the combined cognitive clinic provide consent re willingness to be contacted re research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.